$15M funding aims to advance stem cell therapies for petsJanuary 8, 2024The financing will go toward achieving the conditional U.S. Food and Drug Administration (FDA) approval of Gallant Therapeutic’s candidate for feline chronic gingivostomatitis
SPONSORED CONTENTA Modern Approach to Parasite PreventionWith evolving parasite threats, traditional preventatives may not be enough. Discover how innovation is changing the landscape of protection. + Learn More
Gallant Therapeutics announces study for feline stem cell therapyDecember 18, 2023Gallant Therapeutics, an animal health biotechnology company announced the launch of a study to evaluate the safety and efficacy of its novel allogeneic stem cell therapy candidate to support FDA conditional approval in cats with refractory feline chronic gingivostomatitis (FCGS), the JEDI study.
VPN Plus+ ExclusiveTreating canine osteoarthritis without opioidsMarch 4, 2021There is no reason to mask dogs’ arthritis pain with drugs. There are several techniques available to veterinarians that not only safely and effectively treat osteoarthritis pain, they can address its root cause: inflamed and damaged joints.
Researchers review mesenchymal stem cell therapy potentialApril 18, 2018 In a review published in the Journal of Feline Medicine and Surgery, Jessica M. Quimby, DVM, Ph.D., DACVIM, Department of Veterinary Clinical Sciences at The Ohio State University, and Dori L. Borjesson, DVM, MPVM, Ph.D., Veterinary Institute for Regenerative Cures at the University of California, Davis, consider both the current and potential clinical applications of mesenchymal stem cell therapy in cats. The use of bone marrow-derived stem cells is established for the treatment of human cancer patients and, as such, veterinary applications for bone marrow- and adipose-derived stem cells are being evaluated. In their review, Drs. Quimby and Borjesson consider the emergence of this trend, as well as the current understanding of the biology/immunology of mesenchymal stem cells. Additionally, the authors analyze previous use of mesenchymal stem cells in the treatment of a number of inflammatory, degenerative, and immune-mediated diseases of cats. Traditionally, managing such conditions relies on a lifelong use of medication, with the potential for associated side effects. Often, cats do not respond to standard treatment strategies and, thus, the medication may not protect against the progression of the underlying disease. So far, applications of mesenchymal stem cell therapy in cats have produced encouraging results, including …
Can allogenic stem cells treat canine atopic dermatitis?November 7, 2017 VetCell Therapeutics, a pet-focused cell therapy division of PrimeGen Biotech, announced it will partner in a collaborative clinical study with Western University of Health Sciences, College of Veterinary Medicine to study the feasibility of treating canine atopic dermatitis (AD) with mesenchymal stem cells (MSC). The project's goal is to determine if allogeneic MSCs can serve as a safe, effective, and more extended treatment alternative to corticosteroids and other medical strategies for treating canine AD. The project will be led by the principal investigators Jijun Hao, Ph.D., assistant professor, and Gagandeep Kaur, DVM, Ph.D., a veterinarian and assistant professor, both at Western University of Health Sciences. VetCell Therapeutics will supply allogeneic MSCs for the study. Recently, cell therapies using MSCs have emerged as a novel approach to treating various chronic and degenerative diseases due to the cells' ability to modulate the immune system and control inflammation, according to VetCell Therapteutics. The company said it believes this can aid in relieving symptoms associated with AD. In addition, MSCs boast properties of low immunogenicity making them a promising, low-risk cell-based therapy, the company added. According to VetCell Therapeutics, it produces its MSCs …
The trends to watch for in the veterinary worldJuly 27, 2017Trend watching is must for those who run any type of business—and veterinary practices are no different. Some up-and-coming concepts and upstarts might seem disruptive and intimidating, but it’s better to be at the front end of the knowledge curve.
